P2RY12 and COVID-19: We hypothesized that a focus on antagonism of the P2Y12 receptor pathway alone would be beneficial in patients with COVID-19 by modulating not only platelet aggregation and thrombosis but also platelet-mediated inflammation.22,23 As such, the ACTIV-4a platform focused antiplatelet investigations on potent P2Y12 inhibitors and specifically ticagrelor.